
CLAIMS

1. A compound represented by the general formula (I):

[Chem. 1]



(I)

or a pharmaceutically acceptable salt thereof,

wherein

R^1 is any one of the following a) to d):

a) a cyano group,

b) a carbamoyl group,

c) a C_{2-7} alkoxycarbonyl group, or

d) a carboxy group;

R^2 and R^3 are each independently a hydrogen atom, a C_{1-6} alkyl group, a C_{1-7} acyl group, or a C_{2-7} alkoxycarbonyl group;

R^4 is a hydrogen atom, a C_{1-6} alkyl group, or a halo-C_{1-6} alkyl group;

R^5 is any one of the following a) to j):

a) a C_{1-6} alkyl group,

b) a halo-C_{1-6} alkyl group,

c) a cycloalkyl group,

d) a benzo-fuzed cycloalkyl group,

e) a cycloalkyl-C_{1-6} alkyl group,

f) an aralkyl group, wherein the ring of the aralkyl group is unsubstituted or substituted with 1 to 5 substituents independently selected from the group consisting of a halogen atom, a C_{1-6} alkyl group, a halo-C_{1-6} alkyl group, a C_{1-6} alkoxy group, and a hydroxy-C_{1-6} alkyl group,

g) a heteroaryl-C_{1-6} alkyl group, wherein the ring of the heteroaryl-C_{1-6} alkyl group is unsubstituted or substituted with 1 to 3 substituents independently selected from the group consisting of a C_{1-6} alkyl group, a halo-C_{1-6} alkyl group, and a C_{1-6} alkoxy group,

h) a C_{2-6} alkenyl group,

i) a C_{1-6} alkoxy-C_{1-6} alkyl group, or

j) a $R^{10}R^{11}N$-C_{1-6} alkyl group

R^6 and R^7 are each independently any one of the following a) to k):

a) a hydrogen atom,

b) a C_{1-6} alkyl group,

c) a halo-C_{1-6} alkyl group,

d) a heterocycloalkyl group,

e) a heterocycloalkyl-C_{1-6} alkyl group,

f) an aralkyl group, wherein the ring of the aralkyl group is unsubstituted or substituted with 1 to 5 substituents independently selected from the group consisting of a halogen atom, a C_{1-6} alkyl group, a halo-C_{1-6} alkyl group, a C_{1-6} alkoxy group, and a $R^{10}R^{11}N$-C_{1-6} alkyl group,

g) a heteroaryl-C_{1-6} alkyl group, wherein the ring of the heteroaryl-C_{1-6} alkyl group is unsubstituted or substituted with 1 to 3 substituents independently selected from the group consisting of a C_{1-6} alkyl group, a halo-C_{1-6} alkyl group, and a C_{1-6} alkoxy group,

h) a C_{1-6} alkoxy-C_{1-6} alkyl group,

i) a $R^{12}R^{13}N$-C_{1-6} alkyl group,

j) a $R^{12}R^{13}N$-C_{1-6} alkoxy-C_{1-6} alkyl group, or

k) a $R^{12}R^{13}N$-C(O)-C_{1-6} alkyl group;

R^{10} and R^{11} are each independently a hydrogen atom, a C_{1-6} alkyl group or a hydroxy-C_{1-6} alkyl group, or R^{10} and R^{11}, together with the nitrogen atom to which they are bonded, form a cyclic amino group unsubstituted or substituted with 1 or 2 C_{1-6} alkyl groups; and

R^{12} and R^{13} are each independently a hydrogen atom, a C_{1-6} alkyl group, a hydroxy-C_{1-6} alkyl group or an aryl group, or R^{12} and R^{13}, together with the nitrogen atom to which they are bonded, form a cyclic amino group unsubstituted or substituted with 1 or 2 C_{1-6} alkyl groups.

2. The compound according to claim 1, or a pharmaceutically acceptable salt thereof, wherein R^1 is a cyano group.

3. The compound according to claim 2, or a pharmaceutically acceptable salt thereof, wherein R^2 and R^3 are a hydrogen atom.

4. The compound according to claim 3, or a pharmaceutically acceptable salt thereof, wherein R^4 is a hydrogen atom or a C_{1-6} alkyl group.

5. The compound according to claim 4, or a pharmaceutically acceptable salt thereof, wherein

R^6 is a hydrogen atom; and

R^7 is any one of the following a) to i):

a) a C_{1-6} alkyl group,

b) a halo-C_{1-6} alkyl group,

c) a heterocycloalkyl-C_{1-6} alkyl group,

d) an aralkyl group, wherein the ring of the aralkyl group is unsubstituted or

substituted with 1 to 5 substituents independently selected from the group consisting of a halogen atom, a C_{1-6} alkyl group, a halo-C_{1-6} alkyl group, a C_{1-6} alkoxy group, and a $R^{10}R^{11}N$-C_{1-6} alkyl group,

e) a heteroaryl-C_{1-6} alkyl group, wherein the ring of the heteroaryl-C_{1-6} alkyl group is unsubstituted or substituted with 1 to 3 substituents independently selected from the group consisting of a C_{1-6} alkyl group, a halo-C_{1-6} alkyl group, and a C_{1-6} alkoxy group,

f) a C_{1-6} alkoxy-C_{1-6} alkyl group,

g) a $R^{12}R^{13}N$-C_{1-6} alkyl group,

h) a $R^{12}R^{13}N$-C_{1-6} alkoxy-C_{1-6} alkyl group, or

i) a $R^{12}R^{13}N$-C(O)-C_{1-6} alkyl group.

6. The compound according to claim 5, or a pharmaceutically acceptable salt thereof, wherein

R^5 is any one of the following a) to h):

a) a C_{1-6} alkyl group,

b) a halo-C_{1-6} alkyl group,

c) a cycloalkyl-C_{1-6} alkyl group,

d) an aralkyl group, wherein the ring of the aralkyl group is unsubstituted or substituted with 1 to 5 substituents independently selected from the group consisting of a halogen atom, a C_{1-6} alkyl group, a halo-C_{1-6} alkyl group, a C_{1-6} alkoxy group, and a hydroxy-C_{1-6} alkyl group,

e) a heteroaryl-C_{1-6} alkyl group, wherein the ring of the heteroaryl-C_{1-6} alkyl group is unsubstituted or substituted with 1 to 3 substituents independently selected from the group consisting of a C_{1-6} alkyl group, a halo-C_{1-6} alkyl group, and a C_{1-6} alkoxy group,

f) a C_{2-6} alkenyl group,

g) a C_{1-6} alkoxy-C_{1-6} alkyl group, or

h) a $R^{10}R^{11}N$-C_{1-6} alkyl group.

7. The compound according to claim 6, or a pharmaceutically acceptable salt thereof, wherein

R^6 is a hydrogen atom; and

R^7 is: any one of the following a) to f)

a) a C_{1-6} alkyl group,

b) a halo-C_{1-6} alkyl group,

c) an aralkyl group, wherein the ring of the aralkyl group is unsubstituted or substituted with 1 to 5 substituents independently selected from the group consisting of a halogen atom, a C_{1-6} alkyl group, a halo-C_{1-6} alkyl group, a C_{1-6} alkoxy group, and a $R^{10}R^{11}N$-C_{1-6} alkyl group,

d) a heteroaryl-C_{1-6} alkyl group, wherein the ring of the heteroaryl-C_{1-6} alkyl group is unsubstituted or substituted with 1 to 3 substituents independently selected from the group consisting of a C_{1-6} alkyl group, a halo-C_{1-6} alkyl group, and a C_{1-6} alkoxy group,

e) a C_{1-6} alkoxy-C_{1-6} alkyl group, or

f) a $R^{12}R^{13}N$-C_{1-6} alkyl group.

8. The compound according to claim 7, or a pharmaceutically acceptable salt thereof, wherein

R^4 is a methyl group;

R^5 is any one of the following a) to f):

a) a C_{1-6} alkyl group,

b) a cycloalkyl-C_{1-6} alkyl group,

c) an aralkyl group, wherein the ring of the aralkyl group is unsubstituted or

substituted with 1 to 5 substituents independently selected from the group consisting of a halogen atom, a C_{1-6} alkyl group, a halo-C_{1-6} alkyl group, a C_{1-6} alkoxy group, and a hydroxy-C_{1-6} alkyl group,

d) a heteroaryl-C_{1-6} alkyl group, wherein the ring of the heteroaryl-C_{1-6} alkyl group is unsubstituted or substituted with 1 to 3 substituents independently selected from the group consisting of a C_{1-6} alkyl group, a halo-C_{1-6} alkyl group, and a C_{1-6} alkoxy group,

e) a C_{1-6} alkoxy-C_{1-6} alkyl group, or

f) a $R^{10}R^{11}N$-C_{1-6} alkyl group;

R^6 is a hydrogen atom, and

R^7 is any one of the following a) to d):

a) a C_{1-6} alkyl group,

b) an aralkyl group, wherein the ring of the aralkyl group is unsubstituted or substituted with 1 to 5 substituents independently selected from the group consisting of a halogen atom, a C_{1-6} alkyl group, a halo-C_{1-6} alkyl group, a C_{1-6} alkoxy group, and a $R^{10}R^{11}N$-C_{1-6} alkyl group,

c) a heteroaryl-C_{1-6} alkyl group, wherein the ring of the heteroaryl-C_{1-6} alkyl group is unsubstituted or substituted with 1 to 3 substituents independently selected from the group consisting of a C_{1-6} alkyl group, a halo-C_{1-6} alkyl group, and a C_{1-6} alkoxy group, or

d) a $R^{12}R^{13}N$-C_{1-6} alkyl group.

9. The compound according to claim 8, or a pharmaceutically acceptable salt thereof, wherein

R^5 is any one of the following a) to d):

a) a C_{1-6} alkyl group,

b) a cycloalkyl-C_{1-6} alkyl group,

c) a C_{1-6} alkoxy-C_{1-6} alkyl group, or

d) a $R^{10}R^{11}N$-C_{1-6} alkyl group; and

R^7 is any one of the following a) to b):


a) a C_{1-6} alkyl group, or

b) a $R^{12}R^{13}N$-C_{1-6} alkyl group.

10. The compound according to claim 1, or a pharmaceutically acceptable salt thereof, wherein

the compound is represented by the general formula (II):

[Chem. 2]




(II)

in which the configuration at 4a, 6 and 8a positions is represented by a relative configuration.

11. The compound according to claim 1, or a pharmaceutically acceptable salt thereof, wherein

the compound is represented by the general formula (III):

[Chem. 3]



(III)

in which the configuration at 4a, 6 and 8a positions is represented by an absolute configuration.

12. A compound selected from the group consisting of:

1-{[(4aR, 6R, 8aR)-2-amino-3-cyano-8-methyl-4H, 4aH, 5H, 6H, 7H, 8H, 8aH, 9H-thieno[3,2-g]quinolin-6-yl]carbonyl}-3-[2-(dimethylamino)ethyl]-1-propylurea;

1-{[(4aR, 6R, 8aR)-2-amino-3-cyano-8-methyl-4H, 4aH, 5H, 6H, 7H, 8H, 8aH, 9H-thieno[3,2-g]quinolin-6-yl]carbonyl}-1-butyl-3-[2-(diethylamino)ethyl]urea;

1-{[(4aR, 6R, 8aR)-2-amino-3-cyano-8-methyl-4H, 4aH, 5H, 6H, 7H, 8H, 8aH, 9H-thieno[3,2-g]quinolin-6-yl]carbonyl}-3-[3-(dimethylamino)-2,2-dimethylpropyl]-1-ethlylurea;

1-{[(4aR, 6R, 8aR)-2-amino-3-cyano-8-methyl-4H, 4aH, 5H, 6H, 7H, 8H, 8aH, 9H-thieno[3,2-g]quinolin-6-yl]carbonyl}-3-ethyl-1-[2-(pyrrolidin-1-yl)ethyl]urea;

1-{[(4aR*, 6R*, 8aR*)-2-amino-3-cyano-8-methyl-4H, 4aH, 5H, 6H, 7H, 8H, 8aH, 9H-thieno[3,2-g]quinolin-6-yl]carbonyl}-1-butyl-3-[2-(dimethylamino)-ethyl]urea;

1-{[(4aR*, 6R*, 8aR*)-2-amino-3-cyano-8-methyl-4H, 4aH, 5H, 6H, 7H, 8H, 8aH, 9H-thieno[3,2-g]quinolin-6-yl]carbonyl}-3-[2-(dimethylamino)ethyl]-1-(2-phenylethyl)urea;

1-{[(4aR*, 6R*, 8aR*)-2-amino-3-cyano-8-methyl-4H, 4aH, 5H, 6H, 7H, 8H,

8aH, 9H-thieno[3,2-g]quinolin-6-yl]carbonyl}-3-[2-(dimethylamino)ethyl]-1-(3-methylbutyl)urea;

1-{[(4aR*, 6R*, 8aR*)-2-amino-3-cyano-8-methyl-4H, 4aH, 5H, 6H, 7H, 8H, 8aH, 9H-thieno[3,2-g]quinolin-6-yl]carbonyl}-1-butyl-3-[2-(piperidin-1-yl)ethyl]urea;

1-{[(4aR*, 6R*, 8aR*)-2-amino-3-cyano-8-methyl-4H, 4aH, 5H, 6H, 7H, 8H, 8aH, 9H-thieno[3,2-g]quinolin-6-yl]carbonyl}-3-[2-(dimethylamino)ethyl]-1-(2,2-dimethylpropyl)urea;

1-{[(4aR, 6R, 8aR)-2-amino-3-cyano-8-methyl-4H, 4aH, 5H, 6H, 7H, 8H, 8aH, 9H-thieno[3,2-g]quinolin-6-yl]carbonyl}-3-[(2S)-1-(dimethylamino)propan-2-yl]-1-ethylurea;

1-{[(4aR*, 6R*, 8aR*)-2-amino-3-cyano-8-methyl-4H, 4aH, 5H, 6H, 7H, 8H, 8aH, 9H-thieno[3,2-g]quinolin-6-yl]carbonyl}-3-[2-(dimethylamino)-2-methylpropyl]-1-propylurea;

1-{[(4aR*, 6R*, 8aR*)-2-amino-3-cyano-8-methyl-4H, 4aH, 5H, 6H, 7H, 8H, 8aH, 9H-thieno[3,2-g]quinolin-6-yl]carbonyl}-3-[2-(dimethylamino)-2-ethylbutyl]-1-ethylurea;

1-{[(4aR, 6R, 8aR)-2-amino-3-cyano-8-methyl-4H, 4aH, 5H, 6H, 7H, 8H, 8aH, 9H-thieno[3,2-g]quinolin-6-yl]carbonyl}-1-(cyclopropylmethyl)-3-[3-(dimethylamino)-2,2-dimethylpropyl]urea;

1-{[(4aR, 6R, 8aR)-2-amino-3-cyano-8-methyl-4H, 4aH, 5H, 6H, 7H, 8H, 8aH, 9H-thieno[3,2-g]quinolin-6-yl]carbonyl}-3-[2-(diethylamino)ethyl]-1-ethylurea;

1-{[(4aR, 6R, 8aR)-2-amino-3-cyano-8-methyl-4H, 4aH, 5H, 6H, 7H, 8H, 8aH, 9H-thieno[3,2-g]quinolin-6-yl]carbonyl}-3-[1-(dimethylamino)-2-methylpropan-2-yl]-1-ethylurea;

1-{[(4aR, 6R, 8aR)-2-amino-3-cyano-8-methyl-4H, 4aH, 5H, 6H, 7H, 8H, 8aH, 9H-thieno[3,2-g]quinolin-6-yl]carbonyl}-3-[2-(dimethylamino)-2-ethylbutyl]-1-ethylurea;

1-{[(4aR, 6R, 8aR)-2-amino-3-cyano-8-methyl-4H, 4aH, 5H, 6H, 7H, 8H, 8aH, 9H-thieno[3,2-g]quinolin-6-yl]carbonyl}-3-[2-(dimethylamino)ethyl]-1-ethylurea; and

1-{[(4aR, 6R, 8aR)-2-amino-3-cyano-8-methyl-4H, 4aH, 5H, 6H, 7H, 8H, 8aH, 9H-thieno[3,2-g]quinolin-6-yl]carbonyl}--1-(cyclopropylmethyl)-3-[2-(dimethylamino)ethyl]urea;

or a pharmaceutically acceptable salt thereof.

13. A pharmaceutical composition which comprises a compound according to any one of claims 1 to 12 or a pharmaceutically acceptable salt thereof.

14. A pharmaceutical agent comprising (1) a compound according to any one of claims 1 to 12 or a pharmaceutically acceptable salt thereof, and (2) at least one anti-Parkinson drug selected from L-dopa, dopamine D_2 receptor agonists, anticholinergic agents, adenosine A_{2A} receptor antagonists, NMDA receptor antagonists, monoamine oxidase B inhibitors, COMT inhibitors, aromatic L-amino acid decarboxylase inhibitors, droxidopa, melevodopa, threodops, zonisamide and amantadine hydrochloride.


CLAIMS

The invention claimed is:

1. A compound represented by the general formula (I):

[Chem. 1]

(I)



or a pharmaceutically acceptable salt thereof,
wherein
R^1 is
a cyano group,
R^2 and R^3 are each a hydrogen atom;
R^4 is a hydrogen atom, a C_{1-6} alkyl group, or a halo-C_{1-6} alkyl group;
R^5 is any one of the following a) to j):
a) a C_{1-6} alkyl group,
b) a halo-C_{1-6} alkyl group,
c) a cycloalkyl group,
d) a benzo-fuzed cycloalkyl group,
e) a cycloalkyl-C_{1-6} alkyl group,
f) an aralkyl group, wherein the ring of the aralkyl group is unsubstituted or substituted with 1 to 5 substituents independently selected from the group consisting of a halogen atom, a C_{1-6} alkyl group, a halo-C_{1-6} alkyl group, a C_{1-6} alkoxy group, and a hydroxy-C_{1-6} alkyl group,
g) a heteroaryl-C_{1-6} alkyl group, wherein the ring of the heteroaryl-C_{1-6} alkyl group is unsubstituted or substituted with 1 to 3 substituents independently selected from the group consisting of a C_{1-6} alkyl group, a halo-C_{1-6} alkyl group, and a C_{1-6} alkoxy group,

h) a C_{2-6} alkenyl group,
i) a C_{1-6} alkoxy-C_{1-6} alkyl group, or
j) a $R^{10}R^{11}N$—C_{1-6} alkyl group;
R^6 and R^7 are each independently any one of the following a) to k):
a) a hydrogen atom,
b) a C_{1-6} alkyl group,
c) a halo-C_{1-6} alkyl group,
d) a heterocycloalkyl group,
e) a heterocycloalkyl-C_{1-6} alkyl group,
f) an aralkyl group, wherein the ring of the aralkyl group is unsubstituted or substituted with 1 to 5 substituents independently selected from the group consisting of a halogen atom, a C_{1-6} alkyl group, a halo-C_{1-6} alkyl group, a C_{1-6} alkoxy group, and a $R^{10}R^{11}N$—C_{1-6} alkyl group,
g) a heteroaryl-C_{1-6} alkyl group, wherein the ring of the heteroaryl-C_{1-6} alkyl group is unsubstituted or substituted with 1 to 3 substituents independently selected from the group consisting of a C_{1-6} alkyl group, a halo-C_{1-6} alkyl group, and
a C_{1-6} alkoxy group,
h) a C_{1-6} alkoxy-C_{1-6} alkyl group,
i) a $R^{12}R^{13}N$—C_{1-6} alkyl group,
j) a $R^{12}R^{13}N$—C_{1-6} alkoxy-C_{1-6} alkyl group, or
k) a $R^{12}R^{13}N$—C(O)—C_{1-6} alkyl group;
R^{10} and R^{11} are each independently a hydrogen atom, a C_{1-6} alkyl group or a hydroxy-C_{1-6} alkyl group, or R^{10} and R^{11}, together with the nitrogen atom to which they are bonded, form a cyclic amino group unsubstituted or substituted with 1 or 2 C_{1-6} alkyl groups; and
R^{12} and R^{13} are each independently a hydrogen atom, a C_{1-6} alkyl group, a hydroxy-C_{1-6} alkyl group or an aryl group, or R^{12} and R^{13}, together with the nitrogen atom to which they are bonded, form a cyclic amino group unsubstituted or substituted with 1 or 2 C_{1-6} alkyl groups.

2. The compound according to claim **1**, or a pharmaceutically acceptable salt thereof, wherein R^4 is a hydrogen atom or a C_{1-6} alkyl group.

3. The compound according to claim **2**, or a pharmaceutically acceptable salt thereof, wherein

R^6 is a hydrogen atom; and

R^7 is any one of the following a) to i):

a) a C_{1-6} alkyl group,

b) a halo-C_{1-6} alkyl group,

c) a heterocycloalkyl-C_{1-6} alkyl group,

d) an aralkyl group, wherein the ring of the aralkyl group is unsubstituted or substituted with 1 to 5 substituents independently selected from the group consisting of a halogen atom, a C_{1-6} alkyl group, a halo-C_{1-6} alkyl group, a C_{1-6} alkoxy group, and a $R^{10}R^{11}N$—C_{1-6} alkyl group,

e) a heteroaryl-C_{1-6} alkyl group, wherein the ring of the heteroaryl-C_{1-6} alkyl group is unsubstituted or substituted with 1 to 3 substituents independently selected from the group consisting of a C_{1-6} alkyl group, a halo-C_{1-6} alkyl group, and

a C_{1-6} alkoxy group,

f) a C_{1-6} alkoxy-C_{1-6} alkyl group,

g) a $R^{12}R^{13}N$—C_{1-6} alkyl group,

h) a $R^{12}R^{13}N$—C_{1-6} alkoxy-C_{1-6} alkyl group, or

i) a $R^{12}R^{13}N$—C(O)—C_{1-6} alkyl group.

4. The compound according to claim **3**, or a pharmaceutically acceptable salt thereof, wherein

R^5 is any one of the following a) to h):

a) a C_{1-6} alkyl group,

b) a halo-C_{1-6} alkyl group,

c) a cycloalkyl-C_{1-6} alkyl group,

d) an aralkyl group, wherein the ring of the aralkyl group is unsubstituted or substituted with 1 to 5 substituents independently selected from the group consisting of a halogen atom, a C_{1-6} alkyl group, a halo-C_{1-6} alkyl group, a C_{1-6} alkoxy group, and a hydroxy-C_{1-6} alkyl group,

e) a heteroaryl-C_{1-6} alkyl group, wherein the ring of the heteroaryl-C_{1-6} alkyl group is unsubstituted or substituted with 1 to 3 substituents independently selected from the group consisting of a C_{1-6} alkyl group, a halo-C_{1-6} alkyl group, and

a C_{1-6} alkoxy group,
f) a C_{2-6} alkenyl group,
g) a C_{1-6} alkoxy-C_{1-6} alkyl group, or
h) a $R^{10}R^{11}N$—C_{1-6} alkyl group.

5. The compound according to claim **2**, or a pharmaceutically acceptable salt thereof, wherein

R^6 is a hydrogen atom; and

R^7 is: any one of the following a) to f)

a) a C_{1-6} alkyl group,
b) a halo-C_{1-6} alkyl group,
c) an aralkyl group, wherein the ring of the aralkyl group is unsubstituted or substituted with 1 to 5 substituents independently selected from the group consisting of a halogen atom, a C_{1-6} alkyl group, a halo-C_{1-6} alkyl group, a C_{1-6} alkoxy group, and a $R^{10}R^{11}N$—C_{1-6} alkyl group,
d) a heteroaryl-C_{1-6} alkyl group, wherein the ring of the heteroaryl-C_{1-6} alkyl group is unsubstituted or substituted with 1 to 3 substituents independently selected from the group consisting of a C_{1-6} alkyl group, a halo-C_{1-6} alkyl group, and
a C_{1-6} alkoxy group,
e) a C_{1-6} alkoxy-C_{1-6} alkyl group, or
f) a $R^{12}R^{13}N$—C_{1-6} alkyl group.

6. The compound according to claim **3**, or a pharmaceutically acceptable salt thereof, wherein

R^4 is a methyl group;

R^5 is any one of the following a) to f):

a) a C_{1-6} alkyl group,
b) a cycloalkyl-C_{1-6} alkyl group,
c) an aralkyl group, wherein the ring of the aralkyl group is unsubstituted or substituted with 1 to 5 substituents independently selected from the group consisting of a halogen atom, a C_{1-6} alkyl group, a halo-C_{1-6} alkyl group, a C_{1-6} alkoxy group, and a hydroxy-C_{1-6} alkyl group,
d) a heteroaryl-C_{1-6} alkyl group, wherein the ring of the heteroaryl-C_{1-6} alkyl group is unsubstituted or substituted with 1 to 3 substituents independently selected from the group consisting of a C_{1-6} alkyl group, a halo-C_{1-6} alkyl group, and


a C_{1-6} alkoxy group,
e) a C_{1-6} alkoxy-C_{1-6} alkyl group, or
f) a $R^{10}R^{11}N$—C_{1-6} alkyl group;
R^6 is a hydrogen atom; and
R^7 is any one of the following a) to d):
a) a C_{1-6} alkyl group,
b) an aralkyl group, wherein the ring of the aralkyl group is unsubstituted or substituted with 1 to 5 substituents independently selected from the group consisting of a halogen atom, a C_{1-6} alkyl group, a halo-C_{1-6} alkyl group, a C_{1-6} alkoxy group, and a $R^{10}R^{11}N$—C_{1-6} alkyl group,
c) a heteroaryl-C_{1-6} alkyl group, wherein the ring of the heteroaryl-C_{1-6} alkyl group is unsubstituted or substituted with 1 to 3 substituents independently selected from the group consisting of a C_{1-6} alkyl group, a halo-C_{1-6} alkyl group, and
a C_{1-6} alkoxy group, or
d) a $R^{12}R^{13}N$—C_{1-6} alkyl group.

7. The compound according to claim **4**, or a pharmaceutically acceptable salt thereof, wherein
R^5 is any one of the following a) to d):
a) a C_{1-6} alkyl group,
b) a cycloalkyl-C_{1-6} alkyl group,
c) a C_{1-6} alkoxy-C_{1-6} alkyl group, or
d) a $R^{10}R^{11}N$—C_{1-6} alkyl group; and
R^7 is any one of the following a) to b):
a) a C_{1-6} alkyl group, or
b) a $R^{12}R^{13}N$—C_{1-6} alkyl group.

8. The compound according to claim **1**, or a pharmaceutically acceptable salt thereof, wherein
the compound is represented by the general formula (II):

[Chem. 2]

(II)




in which the configuration at 4a, 6 and 8a positions is represented by a relative configuration.

9. The compound according to claim **1**, or a pharmaceutically acceptable salt thereof, wherein

the compound is represented by the general formula (III):

[Chem. 3]

(III)



in which the configuration at 4a, 6 and 8a positions is represented by an absolute configuration.

10. A compound selected from the group consisting of:

1-{[(4aR,6R,8aR)-2-amino-3-cyano-8-methyl-4H,4aH,5H,6H,7H, 8H,8aH, 9H-thieno[3,2-g]quinolin-6-yl]carbonyl}-3-[2-(dimethylamino)ethyl]-1-propylurea;

1-{[(4aR,6R,8aR)-2-amino-3-cyano-8-methyl-4H,4aH,5H,6H,7H, 8H,8aH, 9H-thieno[3,2-g]quinolin-6-yl]carbonyl}-1-butyl-3-[2-(diethylamino)ethyl]urea;

1-{[(4aR,6R,8aR)-2-amino-3-cyano-8-methyl-4H,4aH,5H,6H,7H, 8H, 8aH, 9H-thieno[3,2-g]quinolin-6-yl]carbonyl}-3-[3-(dimethylamino)-2,2-dimethylpropyl]-1-ethlylurea;

1-{[(4aR,6R,8aR)-2-amino-3-cyano-8-methyl-4H,4aH,5H,6H,7H, 8H, 8aH, 9H-thieno[3,2-g]quinolin-6-yl]carbonyl}-3-ethyl-1-[2-(pyrrolidin-1-yl)ethyl]urea;

1-{[(4aR*,6R*,8aR*)-2-amino-3-cyano-8-methyl-4H,4aH,5H,6H,7H,8H,8aH,9H-thieno[3,2-g]quinolin-6-yl]carbonyl}-1-butyl-3-[2-(dimethylamino)-ethyl]urea;

1-{[(4aR*,6R*,8aR*)-2-amino-3-cyano-8-methyl-4H,4aH,5H,6H,7H,8H,8aH,9H-thieno[3,2-g]quinolin-6-yl]carbonyl}-3-[2-(dimethylamino)ethyl]-1-(2-phenylethyl)urea;

1-{[(4aR*,6R*,8aR*)-2-amino-3-cyano-8-methyl-4H, 4aH,5H,6H,7H,8H,8aH,9H-thieno[3,2-g]quinolin-6-yl]carbonyl}-3-[2-(dimethylamino)ethyl]-1-(3-methylbutyl)urea;

1-{[(4aR*,6R*,8aR*)-2-amino-3-cyano-8-methyl-4H, 4aH,5H,6H,7H, 8H,8aH,9H-thieno[3,2-g]quinolin-6-yl]carbonyl}-1-butyl-3-[2-(piperidin-1-yl)ethyl]urea;

1-{[(4aR*,6R*,8aR*)-2-amino-3-cyano-8-methyl-4H, 4aH,5H,6H,7H,8H,8aH,9H-thieno[3,2-g]quinolin-6-yl]carbonyl}-3-[2-(dimethylamino)ethyl]-1-(2,2-dimethylpropyl)urea;

1-{[(4aR,6R,8aR)-2-amino-3-cyano-8-methyl-4H,4aH, 5H,6H,7H, 8H, 8aH, 9H-thieno[3,2-g]quinolin-6-yl] carbonyl}-3-[(2S)-1-(dimethylamino)propan-2-yl]-1-ethlylurea;

1-{[(4aR*,6R*,8aR*)-2-amino-3-cyano-8-methyl-4H, 4aH,5H,6H,7H,8H,8aH,9H-thieno[3,2-g]quinolin-6-yl]carbonyl}-3-[2-(dimethylamino)-2-methylpropyl]-1-propylurea;

1-{[(4aR*,6R*,8aR*)-2-amino-3-cyano-8-methyl-4H, 4aH,5H,6H,7H,8H,8aH,9H-thieno[3,2-g]quinolin-6-yl]carbonyl}-3-[2-(dimethylamino)-2-ethylbutyl]-1-ethylurea;

1-{[(4aR,6R,8aR)-2-amino-3-cyano-8-methyl-4H,4aH, 5H,6H,7H,8H,8aH,9H-thieno[3,2-g]quinolin-6-yl]carbonyl}-1-(cyclopropylmethyl)-3-[3-(dimethylamino)-2,2-dimethylpropyl]urea;

1-{[(4aR,6R,8aR)-2-amino-3-cyano-8-methyl-4H,4aH, 5H,6H,7H,8H,8aH,9H-thieno[3,2-g]quinolin-6-yl]carbonyl}-3-[2-(diethylamino)ethyl]-1-ethylurea;

1-{[(4aR,6R,8aR)-2-amino-3-cyano-8-methyl-4H,4aH, 5H,6H,7H,8H,8aH,9H-thieno[3,2-g]quinolin-6-yl]carbonyl}-3-[1-(dimethylamino)-2-methylpropan-2-yl]-1-ethylurea;

1-{[(4aR,6R,8aR)-2-amino-3-cyano-8-methyl-4H,4aH, 5H,6H,7H,8H,8aH,9H-thieno[3,2-g]quinolin-6-yl]carbonyl}-3-[2-(dimethylamino)-2-ethylbutyl]-1-ethylurea;

1-{[(4aR,6R,8aR)-2-amino-3-cyano-8-methyl-4H,4aH, 5H,6H,7H,8H,8aH,9H-thieno[3,2-g]quinolin-6-yl]carbonyl}-3-[2-(dimethylamino)ethyl]-1-ethylurea; and

1-{[(4aR,6R,8aR)-2-amino-3-cyano-8-methyl-4H,4aH, 5H,6H,7H,8H,8aH,9H-thieno[3,2-g]quinolin-6-yl]carbonyl}-1-(cyclopropylmethyl)-3-[2-(dimethylamino) ethyl]urea;

or a pharmaceutically acceptable salt thereof.

11. A pharmaceutical composition which comprises a compound according to claim **1** or a pharmaceutically acceptable salt thereof.

12. A pharmaceutical agent comprising (1) a compound according to claim **1** or a pharmaceutically acceptable salt thereof, and (2) at least one anti-Parkinson drug selected from L-dopa, dopamine D_2 receptor agonists, anticholinergic agents, adenosine A_{2A} receptor antagonists, NMDA receptor antagonists, monoamine oxidase B inhibitors, COMT inhibitors, aromatic L-amino acid decarboxylase inhibitors, droxidopa, melevodopa, threodops, zonisamide and amantadine hydrochloride.

13. A pharmaceutical composition as claimed in claim **9**, which is an agent for treatment of a disease selected from the group consisting of Parkinson's disease, restless legs syndrome and hyperprolactinemia.

14. A pharmaceutical composition as claimed in claim **11**, which is an agent for the treatment of Parkinson's disease.

15. 1-{[(4aR,6R,8aR)-2-amino-3-cyano-8-methyl-4H,4aH,5H,6H,7H,8H,8aH,9H-thieno[3,2-g]quinolin-6-yl]carbonyl}-3-[2-(dimethylamino)ethyl]-1-propylurea, or a pharmaceutically acceptable salt thereof.

16. 1-{[(4aR*,6R*,8aR*)-2-amino-3-cyano-8-methyl-4H,4aH,5H,6H,7H,8H,8aH,9H-thieno[3,2-g]quinolin-6-yl]carbonyl}-1-butyl-3-[2-(piperidin-1-yl)-ethyl]urea, or a pharmaceutically acceptable salt thereof.

17. 1-{[(4aR,6R,8aR)-2-amino-3-cyano-8-methyl-4H,4aH,5H,6H,7H,8H,8aH,9H-thieno[3,2-g]quinolin-6-yl]carbonyl}-3-[2-(dimethylamino)-propan-2-yl]-1-ethylurea, or a pharmaceutically acceptable salt thereof.

18. 1-{[(4aR,6R,8aR)-2-amino-3-cyano-8-methyl-4H,4aH,5H,6H,7H,8H,8aH,9H-thieno[3,2-g]quinolin-6-yl]carbonyl}-3-[2-(dimethylamino)-2-ethylbutyl]-1-ethylurea, or a pharmaceutically acceptable salt thereof.

19. 1-{[(4aR,6R,8aR)-2-amino-3-cyano-8-methyl-4H,4aH,5H,6H,7H,8H,8aH,9H-thieno[3,2-g]quinolin-6-yl]carbonyl}-3-[2-(dimethylamino)ethyl]-1-ethylurea, or a pharmaceutically acceptable salt thereof.